2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
5 citations
,
August 2014 in “Australasian journal of dermatology” Sorafenib can cause delayed skin problems, so patients need careful monitoring.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
April 2017 in “Journal of Investigative Dermatology” Dermal lymphatic vessels help hair growth by affecting hair cycle phases.
7 citations
,
September 2019 in “European Journal of Case Reports in Internal Medicine” Linagliptin may cause hair loss and skin blisters.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
February 1961 in “The Lancet” Some new drugs show potential for treating blood cancers but have serious side effects and need more research.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly”
2 citations
,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
38 citations
,
November 2005 in “Epilepsia” Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.